iBio Inc
IBIO
Company Profile
Business description
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Contact
11750 Sorrento Valley Road
Suite 200
San DiegoCA92121
USAT: +1 302 355-0650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
16
Stocks News & Analysis
stocks
Looking under the hood at Robinhood
We review some of the platform's most popular stocks on 11 different measures of equity-related risk.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,133.10 | 6.20 | 0.08% |
| CAC 40 | 7,837.50 | 38.86 | -0.49% |
| DAX 40 | 22,317.64 | 222.34 | -0.99% |
| Dow JONES (US) | 41,989.96 | 11.80 | -0.03% |
| FTSE 100 | 8,579.12 | 55.68 | -0.64% |
| HKSE | 23,202.53 | 4.31 | -0.02% |
| NASDAQ | 17,449.89 | 150.60 | 0.87% |
| Nikkei 225 | 35,725.87 | 101.39 | 0.28% |
| NZX 50 Index | 12,320.19 | 7.59 | 0.06% |
| S&P 500 | 5,633.07 | 21.22 | 0.38% |
| S&P/ASX 200 | 7,934.50 | 9.30 | 0.12% |
| SSE Composite Index | 3,350.13 | 1.69 | 0.05% |